Docking and 3D-QSAR modeling of cyclin-dependent kinase 5/p25 inhibitors

Journal of Molecular Modeling

Volumn 17, Issue 5, 2011, Pages 1149-1161

  Ul Haq, Zaheer ^a   Uddin, Reaz ^a   Wai, Lam Kok ^b   Wadood, Abdul ^a   Lajis, Nordin Haji ^b  

^a UNIVERSITY OF KARACHI   (Pakistan)

^b UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

3D QSAR; CDK5 p25; CoMFA; CoMSIA; Docking

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 5 INHIBITOR P25; CYCLIN DEPENDENT KINASE INHIBITOR; UNCLASSIFIED DRUG;

ALGORITHM; ARTICLE; CHEMICAL PARAMETERS; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME STRUCTURE; MOLECULAR DOCKING; MOLECULAR MODEL; PRIORITY JOURNAL; RELIABILITY;

AMINO ACID SEQUENCE; BINDING SITES; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 5; DRUG DESIGN; HUMANS; KINETICS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR SEQUENCE DATA; NEURODEGENERATIVE DISEASES; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SEQUENCE HOMOLOGY, AMINO ACID; THERMODYNAMICS;

MAMMALIA;

EID: 79958120537     PISSN: 16102940     EISSN: 09485023     Source Type: Journal    
DOI: 10.1007/s00894-010-0817-2     Document Type: Article

References (40)

1. M Mapelli A Musacchio 2003 The structural perspective on CDK5 Neurosignals 12 164 172 10.1159/000074617 1:CAS:528:DC%2BD3sXpslOisrg%3D (Pubitemid 37548230)
2. M Mapelli L Massimiliano C Crovace MA Seeliger LH Tsai L Meijer A Musacchio 2005 Mechanism of CDK5/p25 binding by CDK inhibitors J Med Chem 48 671 679 10.1021/jm049323m 1:CAS:528:DC%2BD2MXovVKh (Pubitemid 40209090)
3. R Dhavan LH Tsai 2001 A decade of CDK5 Nat Rev Mol Cell Biol 2 749 759 10.1038/35096019 1:CAS:528:DC%2BD3MXnvVajsLg%3D (Pubitemid 33679837)
4. A Gupta LH Tsai 2003 Cyclin-dependent kinase 5 and neuronal migration in the neocortex Neurosignals 12 173 179 10.1159/000074618 1:CAS:528: DC%2BD3sXpslOisrk%3D (Pubitemid 37548231)
5. B Bu J Li P Davies I Vincent 2002 Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model J Neurosci 22 6515 6525 1:CAS:528:DC%2BD38XlvFKnsb0%3D (Pubitemid 35386408)
6. LF Lau MK Ahlijanian 2003 Role of cdk5 in the Pathogenesis of Alzheimer's Disease Neurosignals 12 209 214 10.1159/000074622 1:CAS:528: DC%2BD3sXpslOis78%3D (Pubitemid 37548235)
7. MD Nguyen JP Julien 2003 Cyclin-dependent kinase 5 in amyotrophic lateral sclerosis Neurosignals 12 215 220 10.1159/000074623 1:CAS:528: DC%2BD3sXpslOis7w%3D (Pubitemid 37548236)
8. PD Smith SJ Crocker V Jackson-Lewis KL Jordan-Sciutto S Hayley MP Mount MJ O'Hare S Callaghan RS Slack S Przedborski 2003 Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease Proc Natl Acad Sci USA 100 13650 13655 10.1073/pnas.2232515100 1:CAS:528:DC%2BD3sXptFOitbo%3D (Pubitemid 37444794)
9. J Wang SH Liu YP Fu JH Wang YM Lu 2003 Cdk5 activation induces hippocampal CA1 cell death by directly phosphorylating NMDA receptors Nat Neurosci 6 1039 1047 10.1038/nn1119 1:CAS:528:DC%2BD3sXnsFamtbw%3D (Pubitemid 37186195)
10. T Hosoi M Uchiyama E Okumura T Saito K Ishiguro T Uchida A Okuyama T Kishimoto S Hisanaga 1995 Evidence for cdk5 as a major activity phosphorylating tau protein in porcine brain extract J Biochem 117 741 749 1:CAS:528: DyaK2MXlvFygsr0%3D
11. MR Shiradkar MB Padhalingappa S Bhetalabhotala KC Akula DA Tupe RR Pinninti S Thummanagoti 2007 A novel approach to cyclin-dependent kinase 5/p25 inhibitors: a potential treatment for Alzheimer's disease Bioorg Med Chem 15 6397 6406 10.1016/j.bmc.2007.06.053 1:CAS:528:DC%2BD2sXovFOit7k%3D (Pubitemid 47225153)
12. LF Lau PA Seymour MA Sanner JB Schachter 2002 Cdk5 as a drug target for the treatment of Alzheimer's disease J Mol Neurosci 19 267 273 10.1385/JMN:19:3:267 1:CAS:528:DC%2BD3sXislGgsA%3D%3D (Pubitemid 36051517)
13. CJ Helal MA Sanner CB Cooper T Gant M Adam JC Lucas Z Kang S Kupchinsky MK Ahlijanian B Tate 2004 Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease Bioorg Med Chem Lett 14 5521 5525 10.1016/j.bmcl.2004.09.006 1:CAS:528:DC%2BD2cXos1eju7g%3D (Pubitemid 39346337)
14. JA Bibb GL Snyder A Nishi Z Yan L Meijer AA Fienberg LH Tsai YT Kwon JA Girault AJ Czernik 1999 Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons Nature 402 669 671 10.1038/45251 1:CAS:528:DC%2BD3cXjs1yj (Pubitemid 129516337)
15. Cooper CB, Helal CJ, Sanner MA (2002) EU Patent, EP1, 256, 578 A1
16. KS Kim SD Kimball RN Misra DB Rawlins JT Hunt HY Xiao S Lu L Qian WC Han W Shan 2002 Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities J Med Chem 45 3905 3927 10.1021/jm0201520 1:CAS:528:DC%2BD38XlslKjur0%3D (Pubitemid 35024294)
17. RN Misra H Xiao KS Kim S Lu WC Han SA Barbosa JT Hunt DB Rawlins W Shan SZ Ahmed 2004 N-(cycloalkylamino) acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1, 1-dimethylethyl)-2-oxazolyl] methyl] thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent J Med Chem 47 1719 1728 10.1021/jm0305568 1:CAS:528:DC%2BD2cXhs1yls7k%3D (Pubitemid 38380915)
18. RN Misra H Xiao DK Williams KS Kim S Lu KA Keller JG Mulheron R Batorsky JS Tokarski JS Sack 2004 Synthesis and biological activity of N-aryl-2-aminothiazoles: potent pan inhibitors of cyclin-dependent kinases Bioorg Med Chem Lett 14 2973 2977 10.1016/j.bmcl.2004.02.105 1:CAS:528:DC%2BD2cXjs1amu7Y%3D (Pubitemid 38578421)
19. Pevarello P, Amica R, Villa M, Salom B, Vulpetti A, Varasi M (2000) U.S. Patent 372,832
20. Pevarello P, Amici R, Traquandi G, Villa M, Vulpetti A, Isacchi A (2000) WO Patent 0026203
21. Sanner MA, Helal CJ, Cooper CB (2004) US Patent, U.S.6,720,427 B2.
22. MA Glicksman GD Cuny M Liu B Dobson K Auerbach RL Stein KS Kosik 2007 New Approaches to the Discovery of cdk5 Inhibitors Curr Alzheimer Res 4 547 549 10.2174/156720507783018181 1:CAS:528:DC%2BD1cXisVGqsQ%3D%3D (Pubitemid 350248388)
23. S Leclerc M Garnier R Hoessel D Marko JA Bibb GL Snyder P Greengard J Biernat YZ Wu EM Mandelkow 2001 Indirubins inhibit glycogen synthase kinase-3 and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease J Biol Chem 276 251 260 10.1074/jbc.M002466200 1:CAS:528:DC%2BD3MXmtFSnsA%3D%3D (Pubitemid 32050314)
24. V Ravichandran RK Agrawal 2007 Predicting anti-HIV activity of PETT derivatives: CoMFA approach Bioorg Med Chem Lett 17 2197 2202 10.1016/j.bmcl.2007.01.103 1:CAS:528:DC%2BD2sXjvVaisLc%3D (Pubitemid 46484318)
25. CR Rodrigues TM Flaherty C Springer JH McKerrow FE Cohen 2002 CoMFA and HQSAR of acylhydrazide cruzain inhibitors Bioorg Med Chem Lett 12 1537 1541 10.1016/S0960-894X(02)00189-0 1:CAS:528:DC%2BD38Xjsl2lsbk%3D (Pubitemid 34521930)
26. UR Zaheer-ul-Haq H Yuan PA Petukhov MI Choudhary JD Madura 2008 Receptor-based modeling and 3D-QSAR for a quantitative production of the butyrylcholinesterase inhibitors based on genetic algorithm J Chem Inf Model 48 1092 1103 10.1021/ci8000056 1:CAS:528:DC%2BD1cXltFyqtL8%3D
27. VP Zambre PR Murumkar R Giridhar MR Yadav 2009 Structural investigations of acridine derivatives by CoMFA and CoMSIA reveal novel insight into their structures toward DNA G-quadruplex mediated telomerase inhibition and offer a highly predictive 3d-model for substituted acridines J Chem Inf Model 49 1298 1311 10.1021/ci900036w 1:CAS:528:DC%2BD1MXlt12mt74%3D
28. Tripos (2003) Sybyl 7.3. Tripos Inc, St. Louis, MO
29. M Clark RD Cramer Iii N Van Opdenbosch 1989 Validation of the general purpose tripos 5.2 force field J Comput Chem 10 982 1012 10.1002/jcc.540100804 1:CAS:528:DyaK3cXhtlygsbk%3D
30. A Jakalian DB Jack CI Bayly 2002 Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation J Comput Chem 23 1623 1641 10.1002/jcc.10128 1:CAS:528:DC%2BD38XosF2rt74%3D (Pubitemid 35330860)
31. QUACPAC (2008) version 1.3.1, Openeye scientific software, Inc, Santa Fe, NM, USA, www.eyesopen.com
32. G Jones P Willett RC Glen AR Leach R Taylor 1997 Development and validation of a genetic algorithm for flexible docking J Mol Biol 267 727 748 10.1006/jmbi.1996.0897 1:CAS:528:DyaK2sXis1KntLo%3D (Pubitemid 27170693)
33. G Klebe 1998 Comparative molecular similarity indices analysis: CoMSIA Perspect Drug Discov Des 12 87 104 10.1023/A:1017025803403 (Pubitemid 128488925)
34. Huang CC, Couch GS, Pettersen EF, Ferrin TE (1996) In: Hunter L, Klein TE (eds) In Chimera: an extensible molecular modeling application constructed using standard components. Pacific Symposium on Biocomputing, Big Island, HI, January 3-6. World Scientific Publishing, Singapore, p 724
35. N Akula L Lecanu J Greeson V Papadopoulos 2006 3D QSAR studies of AChE inhibitors based on molecular docking scores and CoMFA Bioorg Med Chem Lett 16 6277 6280 10.1016/j.bmcl.2006.09.030 1:CAS:528:DC%2BD28XhtF2jsr3F (Pubitemid 44709910)
36. H Chen PD Lyne F Giordanetto T Lovell J Li 2006 On evaluating molecular-docking methods for pose prediction and enrichment factors J Chem Inf Model 46 401 415 10.1021/ci0503255 1:CAS:528:DC%2BD2MXhtlShtLvE (Pubitemid 43282131)
37. S Radestock M Bohm H Gohlke 2005 Improving binding mode predictions by docking into protein-specifically adapted potential fields J Med Chem 48 5466 5479 10.1021/jm050114r 1:CAS:528:DC%2BD2MXmsVyit7c%3D (Pubitemid 41209244)
38. L Yu PS Yu E Yee Yen Mui JC McKelvie TPT Pham YW Yap WQ Wong J Wu W Deng BP Orner 2009 Phage display screening against a set of targets to establish peptide-based sugar mimetics and molecular docking to predict binding site Bioorg Med Chem 17 4825 4832 10.1016/j.bmc.2009.03.054 1:CAS:528: DC%2BD1MXnt1Gqtr0%3D
39. CLC sequence viewer vers. 6.3 (CLC bio, Aarhus, Denmark)
40. Molecular Operating Environment MOE (2008)10, C. C. G. I. M., Quebec, Canada